Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TRU-016: Completed Phase Ib/II enrollment

Emergent completed enrollment of about 60 patients who have failed up to 3 previous treatments in the Phase II portion of the open-label, U.S. Phase Ib/II Study 16201 of IV TRU-016 given in 28-day cycles. The Phase

Read the full 370 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE